Compare Immunovant Inc. Common Stock (IMVT) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs BlackRock TCP Capital Corp — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while BlackRock TCP Capital Corp trades at $4.04 (market cap $332.25M). The key difference: Immunovant Inc. Common Stock is far larger — about 19.9× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.19% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and BlackRock TCP Capital Corp for 88 Days on average.
| IMVT | TCPC | |
|---|---|---|
Market Cap | $6.62B | $332.25M |
Volume | 1,131,364 | 567,148 |
Sector | Health | Financials |
52-Week High | $44.96 | $6.20 |
52-Week Low | $17.03 | $3.13 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $5.72B | $1.08B |
Dividend Yield | — | 19.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TCPC trades at $3.94, down 1.25% with a bearish technical outlook. The company reported negative revenue and net income trends from 2024-2026, though recent Q2 2026 earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage and improve liquidity. Analyst sentiment is mixed with 30.77% buy ratings but predominantly hold recommendations.
TCPC faces significant fundamental challenges with declining revenue and negative profitability metrics. The ongoing strategic review and portfolio cleanup may offer long-term value, but investors should weigh the high dividend yield against persistent negative cash flow and earnings trends. Key risks include execution of the strategic review and broader private credit market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
